UNIPHARM GRAND OUEST SRA : revenue, balance sheet and financial ratios

UNIPHARM GRAND OUEST SRA is a French company founded 10 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in TOURVILLE-LA-RIVIERE (76410), this company of category PME shows in 2022 a revenue of 3.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - UNIPHARM GRAND OUEST SRA (SIREN 815043005)
Indicator 2024 2023 2022 2020 2019 2018 2017 2016
Revenue N/C N/C 3 732 295 € 4 094 116 € 3 077 936 € 3 060 470 € 3 466 548 € 3 465 518 €
Net income -10 015 € -292 358 € 123 050 € -19 776 € 2 591 € 21 254 € 7 003 € 12 835 €
EBITDA N/C N/C 106 725 € 86 115 € 13 548 € 44 195 € 22 827 € 37 712 €
Net margin N/C N/C 3.3% -0.5% 0.1% 0.7% 0.2% 0.4%

Revenue and income statement

In 2024, UNIPHARM GRAND OUEST SRA records a net loss of 10 k€. This deficit will reduce equity on the balance sheet.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-10 015 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at -701%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -12%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-701.388%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-12.36%

Solvency indicators evolution
UNIPHARM GRAND OUEST SRA

Sector positioning

Debt ratio
-701.39 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Excellent -50 pts over 3 years

In 2024, the debt ratio of UNIPHARM GRAND OUEST SRA (-701.39) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
-12.36% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average

In 2024, the financial autonomy of UNIPHARM GRAND OUEST SRA (-12.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
49.33 years 2022
2022
Q1: 0.0 years
Med: 0.01 years
Q3: 1.6 years
Watch

In 2022, the repayment capacity of UNIPHARM GRAND OUEST SRA (49.33) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 383.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

383.648

Liquidity indicators evolution
UNIPHARM GRAND OUEST SRA

Sector positioning

Liquidity ratio
383.65 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Excellent

In 2024, the liquidity ratio of UNIPHARM GRAND OUEST SRA (383.65) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
27.21x 2022
2022
Q1: 0.0x
Med: 0.34x
Q3: 4.26x
Excellent

In 2022, the interest coverage of UNIPHARM GRAND OUEST SRA (27.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
UNIPHARM GRAND OUEST SRA

Positioning of UNIPHARM GRAND OUEST SRA in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare UNIPHARM GRAND OUEST SRA with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about UNIPHARM GRAND OUEST SRA

What is the revenue of UNIPHARM GRAND OUEST SRA ?

The revenue of UNIPHARM GRAND OUEST SRA in 2022 is 3.7 M€.

Is UNIPHARM GRAND OUEST SRA profitable?

UNIPHARM GRAND OUEST SRA recorded a net loss in 2024.

Where is the headquarters of UNIPHARM GRAND OUEST SRA ?

The headquarters of UNIPHARM GRAND OUEST SRA is located in TOURVILLE-LA-RIVIERE (76410), in the department Seine-Maritime.

Where to find the tax return of UNIPHARM GRAND OUEST SRA ?

The tax return of UNIPHARM GRAND OUEST SRA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does UNIPHARM GRAND OUEST SRA operate?

UNIPHARM GRAND OUEST SRA operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.